Fox Business - The Power to Prosper
Search Site

Merck

FDA Staff: Merck Sleep Drug Effective; Safety Concerns With Higher Doses

Food and Drug Administration staff said a proposed sleep drug from Merck & Co. (MRK) was effective, but questioned the safety of the product's higher doses.Merck is seeking FDA approval of a drug called suvorexant to treat insomnia. The product will be reviewed Wednesday by the FDA's peripheral and central nervous system advisory committee. The agency released a preliminary review of suvorexant Monday in preparation for the meeting.The product was studied in more than 2,000 patients and one study followed patients for more than a year. FDA staff appeared to be in agreement that the studies showed suvorexant was effective at helping people fall asleep and then stay asleep. However, staff raised concerns about the safety of higher doses. The company is proposing two starting doses of the product, depending on age, and two higher doses of the drug.One medical officer wrote, "suvorexant is effective but not safe at the higher doses mainly studied," citing concerns about next-day driving im...

Read More

  1. Exelixis 1st-Quarter Loss Widened as Revenue Slumps Amid Year-Earlier Impacts

    Exelixis Inc.'s (EXEL) first-quarter loss widened as the biotechnology company's revenue declined mostly owing to $10.7 million in revenue recognized in the year-ear...

  2. MARKET SNAPSHOT: U.S. Stocks Sink; Dow Snaps 4-day Win Streak

    U.S. stocks declined Wednesday as the Federal Reserve said it would keep buying $85 billion in bonds each month, but may cut or increase the program depending on the...

  3. Merck 1st-Quarter Profit Down on Loss of Singulair Exclusivity

    Major drug makers are finding it more difficult than expected to overcome the blow of recent patent expirations, with Merck & Co. (MRK) becoming the second company a...

  4. Wall Street Sinks as Oil Sells Off

    FOX Business: Capitalism Lives HereEnergy and materials stocks were the worst performers on the day as energy futures took a thrashing on the back of a much bigger-t...

  5. Wall Street Thrashed Amid Mounting Economic Worries

    FOX Business: Capitalism Lives HereDisappointing jobs data and swelling oil inventories ignited worries about the global economy, and sent stocks and energy futures ...

  6. U.S. Stocks Pare Losses Slightly After Fed Statement

    Stocks held much of their broad losses midday, as investor jitters spread following disappointing economic data and the Federal Reserve's latest statement showed lit...

  7. MARKET SNAPSHOT: U.S. Stocks Continue Slide After Fed Decision

    U.S. stocks declined Wednesday as the Federal Reserve said it would keep buying $85 billion in bonds each month, but may cut or increase the program, depending on th...

  8. MARKET SNAPSHOT: U.S. Stocks Curb Slide After Fed Decision

    U.S. stocks came off session lows on Wednesday afternoon after the Federal Reserve said it would maintain its current monetary easing, as expected.The Federal Reserv...

  9. MARKET SNAPSHOT: U.S. Stocks Sink Before Federal Reserve Decision

    U.S. stocks dropped sharply Wednesday, with the S&P 500 index retreating from its all-time high, as corporate revenue fell short of estimates, as did data on private...

  10. MARKET SNAPSHOT: U.S. Stocks Drop As Companies Miss On Revenue

    U.S. stocks fell Wednesday as companies from MasterCard Inc. to Merck & Co. Inc. reported quarterly results that fell short on revenue and data on private-sector job...

  11. MARKET SNAPSHOT: U.S. Stocks Drop On Corporate Revenue Misses

    U.S. stocks fell Wednesday as companies from MasterCard Inc. to Merck & Co. Inc. reported quarterly results short on revenue and data missed the mark on private-sect...

  12. Earnings Trigger Volume Spike in Pharma ETF

    On Tuesday, it was Pfizer (NYSE:PFE).Wednesday, it is Merck (NYSE:MRK). Earnings reports from the two pharmaceuticals giants and Dow components have triggered two co...

  1. Pair of Studies Show Power of Immune System to Fight Cancer

    Positive results from two early-stage studies of drugs from Bristol-Myers Squibb Co. (BMY) and Roche Holding AG (RHHBY) provided fresh evidence that the power of the...

  2. Merck KGaA to Reach 2014 Outlook One Year Early, 1Q Profit Up

    German pharmaceutical retailer Merck KGaA (MRK.XE) Tuesday said it expects to achieve the guidance it gave for 2014 already one year earlier, after reporting a solid...

  3. EARNINGS FORECAST TABLE: Merck KGaA 1Q 2013

    The following is a summary of analysts' forecasts for Merck KGaA (MRK.XE) first-quarter results, based on a poll of eight analysts conducted by Dow Jones Newswires (...

  4. AbbVie Chief Scientific Officer John Leonard to Retire

    AbbVie Inc. (ABBV), the pharmaceutical business spun off from Abbott Laboratories (ABT), said its head of research and development will retire from the company.In a ...

  5. Analysis: Drugmakers face more scrutiny of discordant U.S. prices

    The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end.Companies like Pfizer...

  6. Merck sales rep claims sexual bias, seeks over $100 million

    A senior sales representative for Merck & Co has sued the drugmaker for more than $100 million, alleging it discriminates against female employees in terms of pay an...

  7. Merck : FDA Accepts Application for Dissolvable Ragweed Allergy Pill

    Merck & Co. (MRK) said the U.S. Food and Drug Administration has accepted its biologics license application for a dissolvable tablet to treat ragweed pollen allergie...

‹ Prev12345Next ›
Freebase CC-BY
Source: Merck on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL